Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

Chung, Seok-Hwan; Lee, Chan Mi; Zhang, Miqin

doi:10.1039/d2nh00289b

Cited by 11 publications

(7 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although mRNA vaccine technology seems to be the answer to antimicrobial resistance and fast-tracking vaccine developments [ 70 , 71 ], it also has limitations, namely poor stability and difficulties in delivering in areas of interest. Moreover, excessive immunogenicity should be avoided in order to overcome a possible host inflammation or autoimmunity [ 72 ].…”

Section: Challenges and Future Perspectives In Malaria Vaccine Develo...mentioning

confidence: 99%

“…Advances in nanoparticle-based mRNA delivery and, more specifically, the use of lipid-based nanoparticles have allowed mRNA-based therapeutics to become more clinically viable and relevant as a strategy for hepatotropic infectious diseases such as malaria [ 72 , 73 ]. The self-amplifying mRNA vaccine approach has instilled hope in surpassing the high immunogenicity observed in conventional mRNA vaccines.…”

Section: Challenges and Future Perspectives In Malaria Vaccine Develo...mentioning

confidence: 99%

“…More specifically, BioNTech company has already developed the BNT165b1 vaccine, a ribonucleic acid (RNA)-lipid nanoparticle (LNP) encoding for part of the Pf CSP and Phase I clinical trial for assessing its safety, tolerability, and immunogenicity has already been designed (NCT05581641) [ 74 ]. This approach holds promise for the future due to its ability to forgo the need for freezer storage, making it more feasible for delivery and administration in infectious diseases endemic regions [ 6 , 72 ].…”

Section: Challenges and Future Perspectives In Malaria Vaccine Develo...mentioning

confidence: 99%

See 2 more Smart Citations

Malaria Vaccines: From the Past towards the mRNA Vaccine Era

Tsoumani,

Voyiatzaki,

Efstathiou

2023

Vaccines

View full text Add to dashboard Cite

Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite life-cycle have been explored, including subunit vaccines, vectored vaccines, and whole organism vaccines with Mosquirix, a vaccine based on a recombinant protein, as the only currently approved vaccine for Plasmodium falciparum malaria. Despite the aforementioned notable progress, challenges such as antigenic diversity, limited efficacy, resistant parasites escaping protective immunity and the need for multiple doses have hindered the development of a highly efficacious malaria vaccine. The recent success of mRNA-based vaccines against SARS-CoV-2 has sparked renewed interest in mRNA vaccine platforms. The unique mRNA vaccine features, including their potential for rapid development, scalability, and flexibility in antigen design, make them a promising avenue for malaria vaccine development. This review provides an overview of the malaria vaccines’ evolution from the past towards the mRNA vaccine era and highlights their advantages in overcoming the limitations of previous malaria vaccine candidates.

show abstract

Section: Challenges and Future Perspectives In Malaria Vaccine Develo...mentioning

confidence: 99%

Section: Challenges and Future Perspectives In Malaria Vaccine Develo...mentioning

confidence: 99%

Section: Challenges and Future Perspectives In Malaria Vaccine Develo...mentioning

confidence: 99%

See 1 more Smart Citation

Malaria Vaccines: From the Past towards the mRNA Vaccine Era

Tsoumani,

Voyiatzaki,

Efstathiou

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Lipid nanoparticle encapsulated mRNA vaccines have shown promising results in diseases as diverse as viral and bacterial infections and cancers. However yet to be established in skin cancers [ 144 , 145 ]. The ability of mRNA to translate to protein directly precluded many bottlenecks associated with conventional therapeutics besides a higher potential to activate immune components with sustained responses.…”

Section: Nanoimmunotherapeutics and Precision Medicine In Skin Cancer...mentioning

confidence: 99%

Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects

Farhana

2023

IJMS

View full text Add to dashboard Cite

Skin cancers, especially melanomas, present a formidable diagnostic and therapeutic challenge to the scientific community. Currently, the incidence of melanomas shows a high increase worldwide. Traditional therapeutics are limited to stalling or reversing malignant proliferation, increased metastasis, or rapid recurrence. Nonetheless, the advent of immunotherapy has led to a paradigm shift in treating skin cancers. Many state-of-art immunotherapeutic techniques, namely, active vaccination, chimeric antigen receptors, adoptive T-cell transfer, and immune checkpoint blockers, have achieved a considerable increase in survival rates. Despite its promising outcomes, current immunotherapy is still limited in its efficacy. Newer modalities are now being explored, and significant progress is made by integrating cancer immunotherapy with modular nanotechnology platforms to enhance its therapeutic efficacy and diagnostics. Research on targeting skin cancers with nanomaterial-based techniques has been much more recent than other cancers. Current investigations using nanomaterial-mediated targeting of nonmelanoma and melanoma cancers are directed at augmenting drug delivery and immunomodulation of skin cancers to induce a robust anticancer response and minimize toxic effects. Many novel nanomaterial formulations are being discovered, and clinical trials are underway to explore their efficacy in targeting skin cancers through functionalization or drug encapsulation. The focus of this review rivets on theranostic nanomaterials that can modulate immune mechanisms toward protective, therapeutic, or diagnostic approaches for skin cancers. The recent breakthroughs in nanomaterial-based immunotherapeutic modulation of skin cancer types and diagnostic potentials in personalized immunotherapies are discussed.

show abstract

“…In this process, the mRNA technology was able to demonstrate the fastest vaccine development ever seen, suitable for emerging infectious diseases that require a rapid response in situations of local outbreaks or global pandemics [18][19][20][21] . Furthermore, the mRNA vaccine platform is now being used in vaccine development against several other infectious diseases, such as Shingles, RSV, HIV, and Malaria, particularly because of its cost and time-effective advantages compared to traditional vaccine platforms [22][23][24] .…”

mentioning

confidence: 99%

Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models

Lelis,

Byk,

Pustylnikov

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Several COVID-19 vaccines, some more efficacious than others, are now available and deployed, including multiple mRNA- and viral vector-based vaccines. With the focus on creating cost-effective solutions that can reach the low- and medium- income world, GreenLight Biosciences has developed an mRNA vaccine candidate, GLB-COV2-043, encoding for the full-length SARS-CoV-2 Wuhan wild-type spike protein. In pre-clinical studies in mice, GLB-COV2-043 induced robust antigen-specific binding and virus-neutralizing antibody responses targeting homologous and heterologous SARS-CoV-2 variants and a TH1-biased immune response. Boosting mice with monovalent or bivalent mRNA-LNPs provided rapid recall and long-lasting neutralizing antibody titers, an increase in antibody avidity and breadth that was held over time and generation of antigen-specific memory B- and T- cells. In hamsters, vaccination with GLB-COV2-043 led to lower viral loads, reduced incidence of SARS-CoV-2-related microscopic findings in lungs, and protection against weight loss after heterologous challenge with Omicron BA.1 live virus. Altogether, these data indicate that GLB-COV2-043 mRNA-LNP vaccine candidate elicits robust protective humoral and cellular immune responses and establishes our mRNA-LNP platform for subsequent clinical evaluations.

show abstract

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

Abstract: The liver is a vital organ that functions to detoxify the body. Liver cancer and infectious diseases such as influenza and malaria can fatally compromise liver function. mRNA delivery is...

Cited by 11 publications

References 169 publications

Malaria Vaccines: From the Past towards the mRNA Vaccine Era

Malaria Vaccines: From the Past towards the mRNA Vaccine Era

Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects

Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models

Contact Info

Product

Resources

About